Updated results from the Phase 1/2 APEX-01 clinical trial of ARX517 demonstrate continued safety and anti-tumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC). Read more in Urology Times. https://bit.ly/484KUj0 #ProstateCancer #AntibodyDrugConjugate
President at Princeton Property Partners
10moFantastic results!